Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Pinedo

Showing results (251-260 of 569) with videos related to

Pageof 57
Sort By:
Lancet (London, England)|August 31, 1991
Reversible thyroid dysfunction during treatment with GM-CSFK Hoekman, B M von Blomberg-van der Flier, J Wagstaff, et al.
Oncology Reports|April 4, 1998
Effects of tubulin-inhibiting agents in human lung and breast cancer cell lines with different multidrug resistance phenotypesJ van Ark-Otte, G Samelis, G Rubio, et al.
Investigational New Drugs|September 1, 1988
Phase II trial of menogaril in advanced colorectal cancerE E Holdener, W W ten Bokkel Huinink, G Decoster, et al.
British Journal of Cancer|July 1, 1996
p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancerS C Linn, A H Honkoop, K Hoekman, et al.
Blood|December 9, 2000
Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of plateletsH M Verheul, A S Jorna, K Hoekman, et al.
Biochemical Pharmacology|October 23, 2004
A methylester of the glucuronide prodrug DOX-GA3 for improvement of tumor-selective chemotherapyMichelle de Graaf, Tapio J Nevalainen, Hans W Scheeren, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 1994
Biochemical modulation of 'classical' multidrug resistance by BIBW22BS, a potent derivative of dipyridamoleW J Jansen, H M Pinedo, C M Kuiper, et al.
Cancer Treatment Reports|February 1, 1980
Treatment of advanced ovarian carcinoma with a combination of hexmethylmelamine, cyclophosphamide, methotrexate, and 5-fluorourcil (hexa-CAF) in patients with and without previous treatmentJ P Neijt, A C van Lindert, C P Vendrik, et al.
Cancer Research|December 1, 1984
Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicityA Leyva, C J van Groeningen, I Kraal, et al.
International Journal of Cancer|August 15, 1990
Differential sensitivity of multi-drug-resistant and -sensitive cells to resistance-modifying agents and the relation with reversal of anthracycline resistanceG J Schuurhuis, H M Pinedo, H J Broxterman, et al.
Pageof 57

Showing results (251-260 of 569) with videos related to

Sort By:
Pageof 57
Lancet (London, England)|August 31, 1991
Reversible thyroid dysfunction during treatment with GM-CSFK Hoekman, B M von Blomberg-van der Flier, J Wagstaff, et al.
Oncology Reports|April 4, 1998
Effects of tubulin-inhibiting agents in human lung and breast cancer cell lines with different multidrug resistance phenotypesJ van Ark-Otte, G Samelis, G Rubio, et al.
Investigational New Drugs|September 1, 1988
Phase II trial of menogaril in advanced colorectal cancerE E Holdener, W W ten Bokkel Huinink, G Decoster, et al.
British Journal of Cancer|July 1, 1996
p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancerS C Linn, A H Honkoop, K Hoekman, et al.
Blood|December 9, 2000
Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of plateletsH M Verheul, A S Jorna, K Hoekman, et al.
Biochemical Pharmacology|October 23, 2004
A methylester of the glucuronide prodrug DOX-GA3 for improvement of tumor-selective chemotherapyMichelle de Graaf, Tapio J Nevalainen, Hans W Scheeren, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 1994
Biochemical modulation of 'classical' multidrug resistance by BIBW22BS, a potent derivative of dipyridamoleW J Jansen, H M Pinedo, C M Kuiper, et al.
Cancer Treatment Reports|February 1, 1980
Treatment of advanced ovarian carcinoma with a combination of hexmethylmelamine, cyclophosphamide, methotrexate, and 5-fluorourcil (hexa-CAF) in patients with and without previous treatmentJ P Neijt, A C van Lindert, C P Vendrik, et al.
Cancer Research|December 1, 1984
Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicityA Leyva, C J van Groeningen, I Kraal, et al.
International Journal of Cancer|August 15, 1990
Differential sensitivity of multi-drug-resistant and -sensitive cells to resistance-modifying agents and the relation with reversal of anthracycline resistanceG J Schuurhuis, H M Pinedo, H J Broxterman, et al.
Pageof 57